European Pharmaceutical Review

DECEMBER 18, 2023

Developed in partnership with the University of Copenhagen and Denmark’s Statens Serum Institut , the Foundation says this the first vaccines initiative globally to focus solely on understanding how to generate immunity in the airway itself. Any revenue generated by NVAC will be reinvested in NIVI.

Pharmaceutical 94

Pharmaceutical 94

Pharmaceutical Technology

MARCH 7, 2024

Alumis secured $259m in a Series C funding round to develop its clinical-stage pipeline of therapies designed to address immune dysfunction.

59

59

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Safety 93

Safety Leads Patients Pharmaceutical 93

European Pharmaceutical Review

JUNE 27, 2023

AC Immune SA has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy vaccine candidate for Alzheimer’s disease. The anti-Abeta therapy “specifically targets the most toxic forms of Abeta” according to Dr Andrea Pfeifer, CEO of AC Immune SA.

Food and Drug Administration 94

Food and Drug Administration Safety FDA Food 94

European Pharmaceutical Review

SEPTEMBER 20, 2023

Results of a Phase I/II study has revealed that a booster dose of a novel, self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine induces a robust, broadly cross-reactive, and durable immune response in adults. All three vaccines induced robust neutralising immune response against the D614G variant at Day 29.

Leads 94

Leads Pharmaceutical 94

Medgadget

AUGUST 25, 2023

The technology aims to overcome some of the immune evasive tricks that tumors use to circumvent the immune system, some of which can hamper more traditional immunotherapies. Tumors employ a variety of tricks to disguise themselves from the immune system or suppress its activity in recognizing and destroying cancer cells.

Education 92

Education Patients Leads Medicine 92

European Pharmaceutical Review

FEBRUARY 24, 2023

According to the authors of the paper, the condition occurs when enzymes required for the synthesis of amino acids known as aminoacyl-tRNA synthetases are attacked in error by the immune system. Once the cells are returned to the patient’s body, the CAR allows the modified immune cells to specifically target the cells triggering the disease.”

Medicine 128

Medicine Engineering Physicians Patients 128

European Pharmaceutical Review

SEPTEMBER 1, 2023

GlobalData’s research showed that within the clinical trials landscape, there are 36 mRNA-based products being investigated in 65 Phase I-III trials across multiple cancer indications. Additionally, there are 178 mRNA-based oncology therapies in total across all clinical stages of development. subvariant.

Marketing 92

Marketing Sales Competition Pharmaceutical 92

European Pharmaceutical Review

AUGUST 17, 2023

Use of the immune checkpoint inhibitor immunotherapy drug ipilimumab plus nivolumab has been shown to be effective as second-line therapy in metastatic melanoma that is resistant to PD-1 inhibitors. Nivolumab blocks an immune checkpoint protein on T cells called PD-1. Ipilimumab inhibits the protein CTLA-4.

Medicine 82

Medicine Patients Pharmaceutical 82

European Pharmaceutical Review

FEBRUARY 1, 2024

Positive results from the first global study for chimeric antigen receptor (CAR)-antologous T cell (BCMA CAR T) injection (Equecabtagene Autoleucel) in immune-mediated necrotising myopathy (IMNM), suggest that the cell therapy could provide a new therapeutic option for antibody-mediated autoimmune disorders.

Safety 85

Safety Patients Medical Pharmaceutical 85

European Pharmaceutical Review

DECEMBER 15, 2023

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. Keytruda is an immunotherapy that works by increasing the ability of the body’s immune system to help detect and fight tumour cells.

Patients 99

Patients Pharmaceutical 99

European Pharmaceutical Review

JANUARY 30, 2024

Results from a Phase III, randomised, placebo-controlled clinical trial have for the first time in fifty years, demonstrated an overall survival benefit from an adjuvant therapy in kidney cancer. Pembrolizumab targets a “checkpoint” pathway that is key in enabling cancer cells to avoid being destroyed by the immune system.

Patients 91

Patients Pharmaceutical 91

European Pharmaceutical Review

AUGUST 10, 2022

Gilead Sciences has signed a definitive agreement to acquire outstanding share capital of clinical-stage biotechnology company MiroBio for around $405 million. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response. . “We

Networking 87

Networking Leads Pharmaceutical Patients 87

European Pharmaceutical Review

AUGUST 2, 2023

This is an additional ingredient designed to trigger a stronger immune response. Clinical evidence for this authorisation is based on data from a study of 765 adults given a primary vaccination with two doses of the Comirnaty COVID-19 vaccine and who were administred with a booster dose of either Bimervax or Comirnaty.

Medicine 98

Medicine Manufacturing Patients Healthcare 98

pharmaphorum

SEPTEMBER 16, 2022

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.

Leads 120

Leads Patients Medicine FDA 120

European Pharmaceutical Review

MAY 17, 2023

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

Engineering 84

Engineering Side effects Medicine Patients 84

Medgadget

NOVEMBER 15, 2022

Researchers at The University of Texas MD Anderson Cancer Center have developed a nanotechnology platform that can make cancer cells more vulnerable to immune attack in the body. The idea is to make solid tumors more appealing for the immune system by attaching a molecule that acts as an “eat me” signal to white blood cells.

Side effects 100

Side effects Medicine 100

European Pharmaceutical Review

JANUARY 23, 2023

EVX-01 cancer immunotherapy EVX-01 is a peptide-based cancer immunotherapy generated based on gene analysis of a patient’s tumours and on matching with their immune system. Clinical trials of EVX-01 Late last year, Evaxion received FDA approval to proceed with its Phase IIb clinical trial, where this combination was given to patients with MM.

Food and Drug Administration 122

Food and Drug Administration FDA Food Patients 122

European Pharmaceutical Review

JANUARY 4, 2023

The companies will collaborate to advance preclinical development and Gilead will be responsible for clinical development and commercialisation. EVOQ’s technology is designed to enable lymph-targeted delivery of disease-specific antigens that have been optimised to deliver antigens to restore immune tolerance.

Sales 96

Sales Pharmaceutical 96

European Pharmaceutical Review

NOVEMBER 25, 2022

STC-15, a first-in-class ribonucleic acid (RNA) modifying enzyme inhibitor, has been dosed in the first patient in a clinical trial, making it the first molecule targeting an RNA methyltransferase to enter clinical development. First-in-human clinical trial for first RNA modifying enzyme inhibitor.

Patients 86

Patients Safety Medical Pharmaceutical 86

European Pharmaceutical Review

NOVEMBER 18, 2022

“The drug’s potential to delay clinical diagnosis of type 1 diabetes may provide patients with months to years without the burdens of disease.”. The drug binds to certain immune system cells and delays progression to stage 3 type 1 diabetes. Tzield clinical trials that supported the US Food and Drug Administration approval.

Food and Drug Administration 95

Food and Drug Administration FDA Side effects Food 95

European Pharmaceutical Review

NOVEMBER 1, 2023

In its decision to recommend the authorisation, the EMA’s human medicines committee (CHMP) assessed laboratory data showing that the adapted vaccine is able to trigger an adequate immune response against XBB.1.5. 5, it was able to trigger a strong immune response against this strain. The most common side effects with Nuvaxovid XBB.1.5

Side effects 100

Side effects Medicine Safety Marketing 100

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. That’s what makes them such a tricky detective mystery!

Recruitment 95

Recruitment Patients Leads Medicine 95

Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. The company strengthens the translational research collaboration between the US and Ireland.

Medicine 103

Medicine Medical 103

Medgadget

FEBRUARY 28, 2023

The overlap between the nervous and immune systems is increasingly appreciated, and this technology aims to capitalize on this to create a new treatment for inflammatory disease. Simhambhatla: Current treatments for inflammatory diseases act by interfering with key aspects of the innate or adaptive immune response.

Medical 95

Medical Patients FDA Recruitment 95

European Pharmaceutical Review

JANUARY 4, 2024

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). An overactive immune response [is] the hallmark of CRS,” Landgren added. The drug tocilizumab for example, has been used historically to treat CRS from immunotherapies.

Side effects 79

Side effects Food and Drug Administration Patients Medicine 79

Pharmaceutical Technology

APRIL 17, 2023

Clinical-stage biotechnology company Smart Immune has secured $5m in equity investment from the Bill & Melinda Gates Foundation for expediting the development of its thymus-empowered ProTcell platform for the treatment of cancer and infectious diseases. SMART 101 is produced from healthy donor-mobilised peripheral blood.

Patients 52

Patients 52

Medgadget

OCTOBER 27, 2022

With many anti-cancer therapies failing at the clinical trial stage and the ethical considerations of animal studies, there is a need for better in vitro cancer models that allow for advanced therapeutic testing. The models have allowed the researchers to test advanced therapies, including CAR-T immune cell therapies.

Ethics 126

Ethics Engineering Safety Patients 126

Pharmaceutical Technology

FEBRUARY 8, 2024

NiKogene is under clinical development by Kian Immune Cell and currently in Phase I for Pediatric Diffuse Intrinsic Pontine Glioma.

40

40

European Pharmaceutical Review

AUGUST 25, 2022

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. 7 Studies also sought to modify oncolytic viruses with additional genes that more efficiently recruit the patient’s immune system to target tumour cells. suppressing activity.

Side effects 100

Side effects Safety Patients Engineering 100

Pharmaceutical Technology

FEBRUARY 6, 2023

Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections. Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis.

Medical 105

Medical Medicine Patients Pharmaceutical 105

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Manufacturing 114

Manufacturing Engineering Government Leads 114

European Pharmaceutical Review

OCTOBER 20, 2022

Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?mediated What are Tregs and how are they applicable to immune-mediated disease?

Engineering 125

Engineering Side effects Manufacturing Patients 125

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). SinoMab BioScience intends to commence a Phase I clinical trial in China to evaluate SM17’s safety profile. The company dosed the first healthy participant in a Phase I clinical first-in-human (FIH) clinical trial in June 2022.

Food and Drug Administration 109

Food and Drug Administration Food Safety Medical 109

Pharmaceutical Technology

JUNE 30, 2023

Immune Thrombocytopeniais under clinical development by NovelMed Therapeutics and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

52

52

European Pharmaceutical Review

MARCH 11, 2024

In the coming years, the goal is for HIV medicines to be taken in intervals that allow at least three or four months between doses, as well as the ability to take them in the privacy of home as opposed to a health clinic. Having clinical trial designs focused on diversity is important.

Medicine 92

Medicine Pharmacology Healthcare Healthcare 92

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. ” The post AstraZeneca’s intranasal COVID vaccine fails first clinical test appeared first on.

Patients 108

Patients 108